Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G McGuire

Showing results (241-250 of 268) with videos related to

Pageof 27
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|September 23, 2006
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptorsMichael P Hill, Paula Ravenscroft, Steven G McGuire, et al.
Psychiatric Services (Washington, D.C.)|February 4, 2012
Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005Catherine A Fullerton, Arnold M Epstein, Richard G Frank, et al.
Health Services Research|March 29, 2008
Testing for statistical discrimination by race/ethnicity in panel data for depression treatment in primary careThomas G McGuire, John Z Ayanian, Daniel E Ford, et al.
Journal of Health Economics|December 7, 2013
Integrating risk adjustment and enrollee premiums in health plan paymentThomas G McGuire, Jacob Glazer, Joseph P Newhouse, et al.
Psychiatric Services (Washington, D.C.)|April 16, 2015
Measuring Performance in Psychiatry: A Call to ActionSherry A Glied, Bradley D Stein, Thomas G McGuire, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 13, 2016
Improving risk equalization with constrained regressionRichard C van Kleef, Thomas G McGuire, René C J A van Vliet, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 26, 2003
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmosetMichael P Hill, Erwan Bezard, Steven G McGuire, et al.
Health Affairs (Project Hope)|December 6, 2021
Coding-Driven Changes In Measured Risk In Accountable Care OrganizationsMichael E Chernew, Jessica Carichner, Jeron Impreso, et al.
Oncogene|March 3, 2009
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivoC M Lee, M M Hickey, C A Sanford, et al.
The American Journal of Psychiatry|July 31, 2013
The cost of assisted outpatient treatment: can it save states money?Jeffrey W Swanson, Richard A Van Dorn, Marvin S Swartz, et al.
Pageof 27

Showing results (241-250 of 268) with videos related to

Sort By:
Pageof 27
Movement Disorders : Official Journal of the Movement Disorder Society|September 23, 2006
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptorsMichael P Hill, Paula Ravenscroft, Steven G McGuire, et al.
Psychiatric Services (Washington, D.C.)|February 4, 2012
Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005Catherine A Fullerton, Arnold M Epstein, Richard G Frank, et al.
Health Services Research|March 29, 2008
Testing for statistical discrimination by race/ethnicity in panel data for depression treatment in primary careThomas G McGuire, John Z Ayanian, Daniel E Ford, et al.
Journal of Health Economics|December 7, 2013
Integrating risk adjustment and enrollee premiums in health plan paymentThomas G McGuire, Jacob Glazer, Joseph P Newhouse, et al.
Psychiatric Services (Washington, D.C.)|April 16, 2015
Measuring Performance in Psychiatry: A Call to ActionSherry A Glied, Bradley D Stein, Thomas G McGuire, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 13, 2016
Improving risk equalization with constrained regressionRichard C van Kleef, Thomas G McGuire, René C J A van Vliet, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 26, 2003
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmosetMichael P Hill, Erwan Bezard, Steven G McGuire, et al.
Health Affairs (Project Hope)|December 6, 2021
Coding-Driven Changes In Measured Risk In Accountable Care OrganizationsMichael E Chernew, Jessica Carichner, Jeron Impreso, et al.
Oncogene|March 3, 2009
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivoC M Lee, M M Hickey, C A Sanford, et al.
The American Journal of Psychiatry|July 31, 2013
The cost of assisted outpatient treatment: can it save states money?Jeffrey W Swanson, Richard A Van Dorn, Marvin S Swartz, et al.
Pageof 27